Table 3.

Correlation between the site of the metastases and somatic mutation status (in patients who had a single-organ metastatic site)

Liver-onlyLung-onlyNodes-onlyPeritoneum-only
MutationnnPnPnP
KRAS160/434 (36.9)55/96 (57.3)2.3 × 10−427/81 (33.3)0.5414/35 (40.0)0.71
b3.5 × 10−31.0b1.0b
BRAF29/432 (6.7)5/97 (5.2)0.3817/81 (21.0)3.7 × 10−58/36 (22.2)9.2 × 10−4
1.0bb5.6 × 10−4b1.4 × 10−2
NRAS11/432 (2.5)2/95 (2.1)0.583/81 (3.7)0.380/36 (0)0.41
1.0b1.0b1.0b
PIK3CA58/429 (13.5)10/93 (10.8)0.4710/81 (12.3)0.782/35 (5.7)0.14
1.0b1.0b1.0b
MSI (BRAFWT)a6/328 (1.8)1/77 (1.3)0.606/54 (11.1)2.9 × 10−42/24 (8.3)9.7 × 10−2
1.0bb4.4 × 10−31.0b

NOTE: Number of tumors with a mutation in the respective oncogene or with MSI against the total number of specimens tested, with percentages in parentheses.

  • aSince MSI and BRAF mutations significantly cooccurred, data shown for MSI BRAFWT. P values as compared with the frequency of the respective mutation in patients with liver-only metastases (bafter correction for multiple testing, n = 15).